What caused the pre-market volume spike in VIVIMEDLAB.NS stock?

The pre-market spike to **33,907** shares on 07 Jan 2026 raised relative volume to **489.58x**. The move appears liquidity-driven, with no immediate price-moving corporate news. Watch for confirmation in regular hours and SEC filings for fresh catalysts.

What is Meyka AI's short-term price outlook for VIVIMEDLAB.NS stock?

Meyka AI's forecast model projects a monthly figure of **INR 63.98**, comparing to the current **INR 13.61**. This implies model-based upside of **370.02%**, which investors should treat as a high-variance projection, not a guarantee.

Is VIVIMEDLAB.NS stock a buy after the volume spike?

The spike improves tradability but fundamentals remain mixed. Meyka AI assigns a **C+ (HOLD)** grade. Short-term trades can follow momentum, while longer-term investors should wait for margin improvement and stronger liquidity metrics.

Which technical levels should traders watch on NSE for VIVIMEDLAB.NS stock?

Traders should watch resistance near **INR 15.00** and support near the pre-spike level at **INR 13.61**. A sustained close above **INR 15.00** with volume would favour momentum continuation.

IN Stocks

VIVIMEDLAB.NS stock pre-market 07 Jan 2026: 489.58x volume spike signals interest

ByDanny Kontos January 7, 2026

A sharp pre-market volume surge flagged VIVIMEDLAB.NS stock on 07 Jan 2026 as volume jumped to 33,907 shares versus an average of 4,974, a 489.58x relative volume. The surge arrives with the NSE price at INR 13.61 and year high INR 29.40. Traders should note liquidity returned ahead of regular hours, with technical indicators and company fundamentals pointing to mixed risk-reward for short-term trading or hold strategies.